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Abstract
Background: Acute viral infections due to widespread, high contagiousness and rapid development of viruses resistance to used drugs (medicines) is one 
of the greatest challenges of modern medicine. Therefore, the search for new approaches and methods for treatment and prevention of viral etiology is 
very relevant. The aim of this article was to review one such approach called bio-regulatory, which allows us to solve the above problem. It is carried out 
through the use of complex bio-regulatory medications. In this article was reviewed complex bio-regulatory medications for viral diseases – Engystol, 
it is antiviral immunomodulator of German pharmaceutical company “Biologische Heilmittel Heel GmbH” which is widely used in a variety of viral 
diseases in case of children and adults thanks to its favorable safety profile and proven efficacy.
Conclusions: National and foreign doctors in case of many viral diseases have experience of successful long-term use of complex bio-regulatory medications 
Engystol. Results of scientific and clinical studies show that Engystol is universal antiviral immune-modulator with proven efficacy in a wide range of 
viral diseases in children and adults. It has a high safety profile. It is used both independently and as part of complex treatment regimens. It goes well 
with any medicines, reducing their side effects on the body.
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Introduction
According to statistics, most people at least once during 
the year suffer of acute respiratory viral infections (ARVI). But 
incidence of ARVI in paediatric population varies, according 
to data of the World Health Organization, from 5 up to 12 
episodes per year that is more than 2.5-4 times higher than 
among adults. Because of the absence of specific immunity 
in human, respiratory viruses spread rapidly in population, 
causing not only increased morbidity, often with complicated 
course, but also lead to huge economic costs [1, 2, 3].
The so-called childhood diseases (measles, varicella, epidemic 
parotitis, etc.) besides high contagiousness, in case of incorrect 
treatment are dangerous with their complications [4, 5, 6].
Current approaches to treatment and prevention of ARVI 
and other viral infections are imperfect: patients receive a large 
amount of medicines, mainly symptomatic, which often cause 
side effects. Widely used today antiviral agents often do not 
provide sufficient effect, since there is a rapid development of 
resistance of viruses to used medicines [7, 8]. Also, there are diffi-
culties due to age restrictions, inability to use medicines at various 
concomitant pathologies, pregnancy, lactation, early childhood.
In this connection it is important to expand the use of 
pathogenic agents and approaches that will improve both 
efficiency and safety profile of therapy, and reduce duration 
of reception of symptomatic medications with side effects.
What is Engystol?
One such approach, which allows us to solve the above 
problem, is bio-regulatory. It is carried out through the use 
of complex bio-regulatory medications (CBM). Earlier in the 
literature was used the term “antihomotoxic medications” 
(AHTM). CBM include ultralow doses of active ingredients 
that activate drainage and detoxification processes in the body 
that help to restore self-regulation and self-healing. They also 
do not have pharmacokinetics and therefore are not metabo-
lized in organism and do not require additional energy, that 
is, do not exert pharmacological stress [9-11].
Let us consider experience of successful long-term use 
of CBM Engystol by national and foreign doctors in case of 
many viral diseases.
Engystol for many decades demonstrates its high efficiency 
at various viral infections. It has immune-modulatory effect on 
the body – activates production of endogenous interferon, as 
well as other antiviral immune mechanisms. Vincetoxin and 
asclepias acid (components of Vincetoxicum) have impact on 
blood vessels and sympathetic nervous system.
Different dilutions of colloidal sulfur (Sulphur) allow to 
release (recover) disturbed enzymatic intracellular processes 
(-SH-group of enzymes), activate elimination of toxins from 
loose connective tissue of intercellular space (drainage and de-
toxification effect). Results of experiments and clinical studies 
have shown also direct antiviral effect of Engystol [12, 13].
Action mechanisms of Engystol
Studies in vitro showed that Engystol enhances phagocytic 
activity of granulocytes in the human body by 33.5% compa-
red to control cultures. Another study in vitro showed that 
Engystol leads to an increase of phagocytic activity by 20-40% 
(depending on the degree of dilution – 1: 10 or 1: 100) in three 
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different immunoassays: granulocyte test, test for removing 
coal dust and granulocytes bioluminescence test [12].
Further studies in vitro have shown that Engystol conside-
rably increases expression of T-lymphocytes which produce 
interferon-α. This effect was observed in all degrees of dissolu-
tion with no apparent dose-dependent manner. Other studies 
confirmed the effect of Engystol in the increased activity of 
granulocytes, phagocytes and neutrophils: destruction of 
virus-infected and tumor cells [12].
Direct antiviral effect of Engystol
The study in vitro defined percentage of viral activity inhi-
bition with various solutions of Engystol at testing of various 
DNA and RNA viruses [13]. Engystol demonstrated a dose-
dependent antiviral activity against DNA viruses: inhibition 
of adenovirus type 5 by 73%, and herpes simplex virus type 1 
(HSV-1) – by 80%, and in the case of RNA viruses: inhibition 
of respiratory-syncytial virus (RSV) – by 37% and of human 
rhinovirus (HRV) – by 20%. Thus, cytotoxic effects and other 
toxic effects of investigated doses of Engystol were not obser-
ved. The antiviral effect was independent of the activation of 
the cellular interferon system, which, according to the authors, 
indicates a direct antiviral effect of Engystol [12].
Engystol is produced in two medicinal forms – pills and 
injectable solution, which adds flexibility at prescription to 
various categories of patients [14].
Tolerability and efficacy of CBM Engystol had been studi-
ed for years by doctors of various specialties in many countries.
Thus, on the basis of Bogomolets National Medical 
University with the head of Department of childhood 
diseases in charge, major infectious diseases specialist of 
the Ministry of Health of Ukraine Professor S. A. Kramarev 
were developed methodical recommendations approved by 
the Ministry of Health of Ukraine “Alternative methods of 
treatment and prevention of influenza and ARVI in case 
of children”. They set out both traditional and alternative 
schemes of treatment and prevention of the most common 
ARVI in children (influenza, parainfluenza, adenoviral 
infection, and others). In detail authors analyze bio-regu-
lation approach to the treatment of ARVI and influenza, 
as well as provide a detailed description of the used CBM. 
Engystol as the basic CBM is included in all schemes of 
ARVI, respiratory-syncytial virus infection treatment, is 
included in the scheme of treatment of acute viral con-
junctivitis, keratitis, adenoviral tonsillitis, pharyngitis, 
bronchiolitis, and others. In schemes of treatment are 
included also other CBM: antiphlogistic – Traumeel S (3), 
lymphatic-drainage – Lymphomyosot (4), detoxification 
– Echinacea compositum S (5), mucolytic, etc. Detailed 
algorithm on use of Engystol for prophylaxis of viral di-
seases is described in methodological recommendations 
of the Ministry of Health of Ukraine [15].
German doctor Ulrich Vemmer, based on years of experi-
ence of CBM using describes in his work schemes of measles 
and varicella treatment, in which is widely used Engystol as 
basic antiviral medicine [4, 5]. He also suggests using Engystol 
in complex treatment of infectious mononucleosis in order 
to improve overall immunity and as a non-specific antiviral 
agent [17].
Doctor of Medicine Anders Horst (Germany) describes 
patterns of CBM use in treatment of epidemic parotiditis, 
arguing that combination of medicines Engystol and Traumeel 
S reduces duration of illness by about half [6].
Within multicenter study conducted by German doc-
tors Gabriella Gertsberger, Michael Weiser “Homeopathic 
treatment of infections of various origin”, were analyzed data 
on use, therapeutic efficacy and tolerability of the medicine 
Engystol [18]. Totally were analyzed 1479 case studies of the 
practice of 154 physicians in three European countries. The 
main indications for use of CBM Engystol were influenza, in-
fection causing fever and prevention of infections by activation 
of immune system. Additional indications for use of medicine 
have included a variety of acute and chronic diseases of the 
upper respiratory tract, as well as other infectious diseases. 
Medicine Engystol has obvious therapeutic effect when used 
alone or in combination with any other form of therapy. There 
were no adverse effects even in cases where the medicine 
Engystol was used in combination with allopathic drugs [18].
In methodical recommendations “Methods of traditional 
medicine in preventive, rehabilitation and complex therapy of 
patients with influenza and ARVI” of the Ministry of Health 
of Ukraine are presented alternative methods and approaches 
to treatment and prevention of ARVI and influenza, including 
homeopathy, herbal medicine, Su-Jok therapy [16]. A separate 
section is devoted to use of CBM, anti-inflammatory, immu-
ne-modulatory and antiviral medicines, including Engystol.
It is concluded that main advantages of CBM are ease of 
use, appointment according to nosological principle, raw 
materials and finished products quality control. Efficacy, 
safety, no side effects, economic accessibility, possibility of 
combination with allopathic medicines make CBM indispen-
sable for treatment and prevention of influenza in children, 
pregnant women, the elderly, patients with tendency to allergic 
reactions. Simultaneous use of CBM and allopathic medicines 
allows reduced dose of the latter taking by 50% [16].
Engystol usage experience convincingly demonstrated its 
efficiency both in the treatment of ARVI, other viral infections 
and in the cases when viral infection becomes a complication 
factor in injuries and degenerative-inflammatory processes of 
locomotor apparatus.
In our practice Engystol in combination with Traumeel S 
is efficiently used for pain treating in patients whose illness 
preceded, caused or associated viral infection.
Conclusions
Based on the results of scientific and clinical studies, it 
can be concluded that Engystol is universal antiviral immu-
ne-modulator with proven efficacy in a wide range of viral 
diseases in children and adults. It has a high safety profile. It 
is used both independently and as part of complex treatment 
regimens. It goes well with any medicines, reducing their side 
effects on the body.
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